Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
Part of paid clinical trials in Houston, Texas.
- Sponsor
- M.D. Anderson Cancer Center
- Study ID
- NCT05985954
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Metastatic Colorectal Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Cetuximab — DRUGGiven by IV (vein)
- Ulixertinib — DRUGGiven by PO
- Encorafenib — DRUGGiven by PO
Study Details
To find the recommended dose of ulixertinib that can be given in combination with cetuximab and/or encorafenib to patients with unresectable/metastatic CRC and who have received EGFR or BRAF-directed therapy in the past.
Key Dates
- Start date
- Jan 18, 2024
- Status verified
- Mar 2026
- Primary completion
- Mar 28, 2028
- Completion
- Mar 28, 2028
Study Design
- Enrollment
- 27 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: BRAF Expansion Cohort1 of these 2 doses will be selected as the recommended dose of ulixertinib that can be given in combination with cetuximab and encorafenib.
- Experimental: Cohort A1 of these 2 doses will be selected as the recommended dose of ulixertinib that can be given in combination with cetuximab alone.
Primary Outcome Measure
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 [ Time Frame: through study completion; an average of 1 year ]
Central Contacts
- Christine Parseghian, MD(713) 792-2828
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| M D Anderson Cancer Center | Houston | Texas | 77030 | Christine Parseghian, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Houston, TX
By research site
Related Studies
- A Study of ART0380 for the Treatment of Advanced or Metastatic Solid TumorsPHASE1/PHASE2 · Recruiting · Artios Pharma Ltd · Birmingham, Alabama
- A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)PHASE1 · Recruiting · Hoffmann-La Roche · Birmingham, Alabama
- A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C MutationsPHASE1/PHASE2 · Recruiting · M.D. Anderson Cancer Center · Boston, Massachusetts
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsPHASE1 · Recruiting · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Duarte, California